Sugi Predict

Sugi Predict / Compounds / SCHEMBL21884664

SCHEMBL21884664

SCHEMBL21884664

COc1ccc(Cl)c(-c2c(C#N)ccc(O)c2C(=O)NC(=N)N)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F2 P00734 1/20 0.37
▸ F10 P00742 1/20 0.37
▸ PLAU P00749 1/20 0.37
▸ PLAT P00750 1/20 0.37
▸ S1PR3 Q99500 2/20 0.35
▸ S1PR1 P21453 1/20 0.35
▸ MEN1 O00255 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ NPC1 O15118 3/20 0.34
▸ RAB9A P51151 3/20 0.34
▸ TP53 P04637 2/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ SCN10A Q9Y5Y9 2/20 0.34
▸ MAPT P10636 6/20 0.34
▸ KDM4E B2RXH2 4/20 0.34
▸ HPGD P15428 3/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ PIM1 P11309 1/20 0.34
▸ LMNA P02545 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21884458 0.88 S1PR3 (0.37) F2F10PLAUPLATS1PR3
SCHEMBL21884399 0.87 GAA (0.35) F2F10PLAUPLATS1PR3
SCHEMBL21884530 0.86 TMPRSS4 (0.40) F2F10PLAUPLATS1PR3
SCHEMBL21885702 0.85 PPIA (0.35) S1PR3MEN1KMT2AGAA
SCHEMBL21884669 0.83 ALDH1A1 (0.44) F2F10PLAUPLATMEN1
SCHEMBL21884383 0.82 L3MBTL1 (0.38) MEN1KMT2ANPC1RAB9ATP53
SCHEMBL21884460 0.82 BIRC5 (0.40) ALDH1A1HTTCYP3A4CYP2C19
SCHEMBL21884581 0.82 KCNMA1 (0.42) F10S1PR3S1PR1MEN1KMT2A
SCHEMBL21884434 0.82 L3MBTL1 (0.38) S1PR3MEN1KMT2ANPC1RAB9A
SCHEMBL21884671 0.82 ALDH1A1 (0.42) PLAUPLATTP53HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS INC. 2021-12-02 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY JNANA THERAPEUTICS INC. 2021-09-30 — — US disclosed
WO-2020061473-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS JNANA THERAPEUTICS, INC. (US) 2020-03-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210299070-A1 METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY SLC19A1, SLC1A5, SLC1A2 F2 4663/4885F10 4684/4885PLAU 986/4885
US-20210371403-A1 SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS SNRPE, G3BP1, G3BP2 F2 4520/4885F10 4139/4885PLAU 3975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.